Join us on Tuesday 4th February 2025 – 14:00-16:00
This free, non-promotional meeting brings together healthcare professionals from primary and secondary care and aims to provide further understanding and explore the diagnosis of Transthyretin amyloid cardiomyopathy (ATTR-CM) and it’s link to heart failure.
The 2-hour webinar will cover topics such as the types of amyloidosis including differential diagnosis of ATTR-CM, the Pathophysiology of ATTR-CM and the signs and symptoms of ATTR-CM compared with HFpEF/HFrEF. The expert panel from the National Amyloidosis Centre (NAC) will discuss ‘Red flags’ for HCPs that should ‘raise clinical suspicion’ of potential ATTR-CM and look at the diagnostic pathway including imaging (MRI/DPD-Scintigraphy), biopsy and genetic testing. During the webinar you will be educated on the various treatment options and long-term goals and management.
To attend this free event, please book online. You will receive your virtual delegate confirmation and webinar link in 24-hours.
Click here to register
ATTR-CM is an underdiagnosed and potentially fatal disease of the heart muscle.
In ATTR-CM, a protein called transthyretin that normally circulates in the bloodstream becomes misshapen and builds up in the heart, nerves and other organs. When these amyloid deposits build up in the heart, the walls can become stiff, making the left ventricle unable to properly relax and fill with blood (cardiomyopathy). ATTR-CM is a progressive condition that may ultimately lead to heart failure.
Symptoms of ATTR-CM can vary and are subtle, and therefore the condition is often misdiagnosed. In its early stages, it may mimic the symptoms of other conditions, such as heart failure, hypertension and hypertrophic cardiomyopathy. Some patients may have no symptoms, while others may progress to end-stage heart failure.
Once suspected, more specialised tests are needed to confirm the diagnosis.
Agenda
Tuesday 4th February 2025
14:00
Welcome and Learning objectives
Speaker:
Dr Kevin Fernando, GP Partner North Berwick Health Centre, GP with Specialist Interest in CVRM
14:05
Introduction to ATTR-CM including Pathophysiology and differential diagnosis of ATTR-CM and heart failure
Speaker:
Professor Julian Gillmore, Professor of Medicine, UCL Centre for Amyloidosis, National Amyloidosis Centre
14:30
The diagnostic pathway – imaging/tissue biopsy and genetic testing
Speaker:
Christine Chiti, NAC TTR Specialist Nurse, Royal Free London NHS Foundation Trust, National Amyloidosis Centre
14:55
Treatment options and long-term management
Speaker:
Christine Chiti, NAC TTR Specialist Nurse, Royal Free London NHS Foundation Trust, National Amyloidosis Centre
15:20
Patient case studies including red flags for HCPs
Speaker:
Dr Will Moody, Consultant Cardiologist-Imaging and Heart Muscle Disease, Queen Elizabeth Hospital Birmingham, University Hospitals Birmingham NHS Foundation Trust
15:45
Questions and Answers
Speakers:
All speakers and Chair
15:55
Summary and key takeaways
Speakers:
Dr Kevin Fernando, GP Partner North Berwick Health, Centre, GP with Specialist Interest in CVRM
*Agenda subject to change
Speakers
Dr Kevin Fernando
FAcadMEd MSc Diabetes, GP Partner North Berwick Health Centre, GP with Specialist Interest in CVRM & Medical Education, Content Advisor for WebMD Medscape Global & UK and Honorary Clinical Reader at the University of Dundee
Kevin is a part-time GP Partner working at North Berwick Health Centre, near Edinburgh. Kevin is also Scottish lead of the Primary Care Diabetes Society, Content Advisor for WebMD Medscape Global & UK and a co-founder of GoggleDocs.
Kevin graduated from the University of Edinburgh in 2000 and holds both MRCGP and MRCP(UK) qualifications and has completed a Master’s degree in diabetes which he passed with distinction.
Kevin has been elected to Fellowship of the Royal College of General Practitioners, the Royal College of Physicians of Edinburgh and also the Academy of Medical Educators for his work in diabetes and medical education.
Professor Julian Gillmore
Professor of Medicine, UCL Centre for Amyloidosis, National Amyloidosis Centre
Julian Gillmore gained his medical degree at University of London and was appointed Professor of Medicine at University College London in 2017. He trained in nephrology and undertook MD and PhD degrees in the field of amyloidosis. His research interests include pathogenesis, diagnosis and treatment of amyloidosis. He is clinical lead for ATTR amyloidosis at the UK National Amyloidosis Centre. He has published more than 350 articles in journals and international conference proceedings, has supervised a number of students through their research degrees, and holds several grants.
Christine Chiti
NAC TTR Specialist Nurse, Royal Free London NHS Foundation Trust, National Amyloidosis Centre
Christine Chiti, RGN, is a Renal and ATTR Specialist Nurse, providing comprehensive services to a wide variety of patients with ATTR Amyloidosis at the National Amyloidosis Centre. She has recently taken on the role of TTR specialist nurse at the same centre. Christine graduated as a Registered General Nurse in August 2000 with a Diploma in Nursing from Kitwe Central Hospital, Zambia. With nearly 24 years of nursing experience, she has worked in paediatrics, paediatric critical care, trauma, and neurology at Royal National Orthopaedic Hospital, Fresenius Dialysis Centres, and Bart’s Hospital. These positions have allowed her to develop a well-rounded skill set within a multidisciplinary team. Christine firmly believes that a holistic approach is the most effective way to provide quality care to patients with long-term conditions.
Dr. William E. Moody, PhD, MRCP
Consultant Cardiologist-Imaging and Heart Muscle Disease, Queen Elizabeth Hospital Birmingham, University Hospitals Birmingham NHS Foundation Trust
Dr Will Moody is a Consultant Cardiologist at the Queen Elizabeth Hospital Birmingham, with a specialist interest in cardiomyopathy and cardiac imaging. With accreditation in echocardiography, CMR and nuclear cardiac imaging, he is the cardiovascular imaging lead for University Hospitals Birmingham and the clinical lead for the Midlands Amyloidosis Service. Following entry onto the inaugural BCS Emerging Leaders Program, he has used this opportunity to begin establishing a national amyloidosis network, with the aim of achieving earlier diagnosis and improved outcomes for these patients. After being awarded a NIHR Clinical Research Scholarship this year, his current research interests include investigating the role of novel and conventional heart failure therapies in cardiac amyloidosis.
Prices
This event is free for all delegates.